norstictic acid: from Xanthoparmelia chlorochroa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5379540 |
| CHEMBL ID | 228281 |
| SCHEMBL ID | 13287269 |
| MeSH ID | M0551139 |
| Synonym |
|---|
| 571-67-5 |
| 1,3-dihydro-1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo-7h-isobenzofuro(4,5-b)(1,4)benzodioxepin-11-carboxaldehyde |
| 7h-isobenzofuro(4,5-b)(1,4)benzodioxepin-11-carboxaldehyde, 1,3-dihydro-1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo- |
| BRD-A80079592-001-02-4 |
| SPECTRUM_000470 |
| SPECTRUM4_001573 |
| BSPBIO_001909 |
| SPECTRUM5_000226 |
| NCGC00095221-02 |
| NCGC00095221-01 |
| KBIO2_000950 |
| KBIOSS_000950 |
| KBIOGR_002126 |
| KBIO3_001409 , |
| KBIO2_003518 |
| KBIO2_006086 |
| SPECTRUM2_000171 |
| SPBIO_000061 |
| SPECTRUM3_000235 |
| SPECTRUM201716 |
| NCGC00095221-03 |
| CHEMBL228281 |
| norstictic acid |
| HMS1923A11 |
| CCG-38381 |
| bdbm50442875 |
| SCHEMBL13287269 |
| 7h-isobenzofuro[4,5-b][1,4]benzodioxepin-11-carboxaldehyde, 1,3-dihydro-1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo- |
| bryopogonic acid |
| IEVVSJFLBYOUCJ-UHFFFAOYSA-N |
| 1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo-1,3-dihydro-7h-2,6,12-trioxabenzo[5,6]cyclohepta[1,2-e]indene-11-carbaldehyde # |
| SR-05000002624-1 |
| sr-05000002624 |
| 1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo-3,7-dihydro-1h-benzo[e]isobenzofuro[5,4-b][1,4]dioxepine-11-carbaldehyde |
| Q3604544 |
| 1,3-dihydro-1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo-7h-isobenzofuro[4,5-b][1,4]benzodioxepin-11-carboxaldehyde |
| D377V822FG |
| 5,13,17-trihydroxy-7,12-dimethyl-9,15-dioxo-2,10,16-trioxatetracyclo[9.7.0.03,8.014,18]octadeca-1(11),3(8),4,6,12,14(18)-hexaene-4-carbaldehyde |
| BRD-A80079592-001-03-2 |
| 1,4,10-trihydroxy-5,8-dimethyl-3,7-dioxo-1,3-dihydro-7h-2,6,12-trioxabenzo[5,6]cyclohepta[1,2-e]indene-11-carbaldehyde |
| DTXSID30972564 |
| CS-0532648 |
| HY-N10457 |
| norsticticacid |
| GLXC-26028 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norstictic acid treatment significantly suppressed MDA-MB-231/GFP tumor growth of a breast cancer xenograft model in athymic nude mice." | ( Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met. Akl, MR; Bhattacharjee, J; Ebrahim, HY; Egbert, S; El Sayed, KA; Elsayed, HE; Mohyeldin, MM, 2016) | 2.6 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 19.9526 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 6.7833 | 0.0040 | 23.8416 | 100.0000 | AID485290; AID489007 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 7.9433 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 6.3096 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 2.2387 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 6.3096 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 6.3096 | 0.0003 | 11.4484 | 31.6228 | AID900 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 39.8107 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Mediator of RNA polymerase II transcription subunit 25 | Homo sapiens (human) | IC50 (µMol) | 2.3000 | 2.3000 | 2.3000 | 2.3000 | AID1870203 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 (µMol) | 0.5495 | 0.1047 | 2.7195 | 7.0795 | AID977603 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | Ki | 0.4200 | 0.0800 | 2.4688 | 9.8000 | AID977604 |
| 14 kDa phosphohistidine phosphatase | Homo sapiens (human) | IC50 (µMol) | 7.9000 | 7.9000 | 7.9000 | 7.9000 | AID1870205 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 (µMol) | 1.1481 | 0.0500 | 2.3797 | 9.7000 | AID977600 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | Ki | 0.6300 | 0.0440 | 1.3630 | 5.0000 | AID977601 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1870208 | Time dependent inhibition of PHPT1 (unknown origin) at 10 uM using DiFMUP as fluorogenic substrate preincubated for 15 to 120 mins followed by substrate addition and measured for 30 mins by fluorogenic assay | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977600 | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1870216 | Inhibition of LHPP (unknown origin) using pyrophosphate as substrate incubated for 30 mins followed by substrate addition and measured after 30 mins by fluorogenic assay | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID292620 | Superoxide radical scavenging activity | 2007 | Journal of natural products, Jul, Volume: 70, Issue:7 | Stictic acid derivatives from the lichen Usnea articulata and their antioxidant activities. |
| AID1870214 | Reversible inhibition of PHPT1 (unknown origin) at 100 uM using DiFMUP as fluorogenic substrate preincubated for 30 mins followed by substrate addition by dialysis method | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID977603 | pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1870215 | Inhibition of PTP1B (unknown origin) at 10 uM incubated for 30 mins | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID977604 | Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1870205 | Inhibition of PHPT1 (unknown origin) using DiFMUP as fluorogenic substrate incubated for 30 mins followed by substrate addition and measured every 60 seconds for 30 mins by fluorogenic assay | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID1870203 | Inhibition of Med25 transcriptional activation in human MCF-7 cells by fluorescence polarization assay | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID1870212 | Inhibition of PHPT1 (unknown origin) assessed as inactivation constant measured up to 100 uM incubated up to 30 mins using DiFMUP as fluorogenic substrate by fluorogenic assay | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID977601 | Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1316797 | Inhibition of wild type His-tagged translin/trax E126A mutant (unknown origin) coexpressed in Escherichia coli BL21 cells using RNase Alert as substrate at 30 uM incubated for 10 mins prior to substrate addition monitored over 60 mins by fluorescence assa | 2016 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20 | A druggable target for rescuing microRNA defects. |
| AID1870211 | Inhibition of PHPT1 (unknown origin) assessed as inhibition constant measured up to 100 uM incubated up to 30 mins using DiFMUP as fluorogenic substrate by fluorogenic assay | 2022 | ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7 | Inhibitor Screen Identifies Covalent Inhibitors of the Protein Histidine Phosphatase PHPT1. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||